Tiazac XC · DIN 02256738 · 120 mg · extended release tablet
General benefitMarketed · checked November 19, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Tiazac XC · DIN 02256738
Manufacturer: Biovail Pharmaceuticals Canada; listing date 2005-05-25
Health Canada: Marketed since 2021-06-04 · brand TIAZAC XC · ATC C08DB01 DILTIAZEM · form Tablet (extended-release) · route Oral · ingredients DILTIAZEM HYDROCHLORIDE 120 MG · company Bausch health, canada inc. · schedule Prescription
Tiazac XC: Formulary list price $1.09 per unit (the source does not state the unit; exact figure $1.0911). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02256738)
Source record
DIN 02256738: Tiazac XC
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240400161; group id 280; item number 0583; lccId None; manufacturer id BIO
Source form: ER Tab; strength: 120mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.0911; ministry $1.0911
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02256738
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74195
Shortage status: not checked (no credentials)